Conquer Age-Related Decline

Deficient mitophagy contributes to Parkinson's disease and aging itself.

Vincere's small molecules increase mitophagy and have potential to be the first ever medicines to slow or stop Parkinson's disease and other age-related diseases.

To develop these small molecules we have raised equity and grant funding, including research support from expert agencies such as the Michael J. Fox Foundation and NIH.

We have recruited top talent to plan and execute on these projects within an aggressive timeline.

In the past year Vincere has received multiple awards from pharmaceutical companies such as Johnson & Johnson and Bristol Myers Squibb acknowledging the potential of our program.